HCW Biologics (HCWB) Cost of Revenue (2022 - 2025)
HCW Biologics' (HCWB) quarterly Cost of Revenue came in at $21609.0 in Q4 2025, down 93.16% YoY from $315843.0 in Q4 2024, and up 73.08% on a QoQ basis from $12485.0 in Q3 2025.
HCW Biologics (HCWB) Cost of Revenue (2022 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 4 years of Cost of Revenue data on file, last reported at $21609.0 in Q4 2025.
- Quarterly Cost of Revenue fell 93.16% year-over-year to $21609.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43386.0 (down 97.3% YoY) and the FY2025 annual result came in at $43386.0, down 97.3% from the prior year.
- Cost of Revenue grew to $21609.0 in Q4 2025, from $12485.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $1.4 million in Q3 2022 to a low of $4052.0 in Q1 2025.
- A 4-year average of $504245.1 and a median of $389790.5 in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue soared 1644.34% — and 2025, when it plunged 99.21%.
- Tracing HCWB's Cost of Revenue over 4 years: stood at $1.1 million in 2022, then declined by 0.17% to $1.1 million in 2023, then slumped by 70.52% to $315843.0 in 2024, then sank by 93.16% to $21609.0 in 2025.
- The last three Cost of Revenue figures came in at $21609.0 (Q4 2025), $12485.0 (Q3 2025), and $5240.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 298.26 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 67.21 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 387.98 Mn |
| 10 | HCW Biologics | 2.93 Mn | 2.19 Mn | -93,887.00 | 229,455.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21,609.00 |
| Dec 31, 2025 | 21,609.00 |
| Sep 30, 2025 | 12,485.00 |
| Sep 30, 2025 | 12,485.00 |
| Jun 30, 2025 | 5,240.00 |
| Jun 30, 2025 | 5,240.00 |
| Mar 31, 2025 | 4,052.00 |
| Mar 31, 2025 | 4,052.00 |
| Dec 31, 2024 | 315,843.00 |
| Dec 31, 2024 | 315,843.00 |
| Sep 30, 2024 | 341,138.00 |
| Sep 30, 2024 | 341,138.00 |
| Jun 30, 2024 | 438,443.00 |
| Jun 30, 2024 | 438,443.00 |
| Mar 31, 2024 | 511,965.00 |
| Mar 31, 2024 | 511,965.00 |
| Dec 31, 2023 | 1.07 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 678,325.00 |
| Sep 30, 2023 | 678,325.00 |